Ailin: €1,5M raised to diagnose the future from your living room
Meet Ailin, a Barcelona disruptor in health diagnostics, securing €1.5M in a strategic investment round. Backed by visionaries and investors like Decelera Ventures, Ailin pioneers a new health era. CEO Isabel Caruana's dedication fuels innovation, propelling Ailin into AI-driven diagnostics accessible from home. The plan for 2024? Forge alliances, expand kit offerings, and partner with health institutions. Ailin's x7 growth in 2023 isn't just numbers; it's user-centric innovation with a remarkable 72% NPS. Ailin: redefining health diagnostics for a healthier future.
In the world of health diagnostics, bustling with labs and clinics, a Barcelona-based disruptor is rewriting the script. Meet Ailin, a startup on a mission to revolutionize how we approach health, and they're doing it with flair, backed by a recent €1.5 million injection of confidence from both private investors and the public support of CDTI's Neotec program.
From its inception, Ailin has been a trailblazer, initially kickstarting its journey with funds from FFF. Despite market challenges, the startup has not only weathered the storm but has set sail far beyond their initial expectations. Their recent investment round, championed by a family office deeply rooted in the health sector, spells out a strategic move. Business angels with private equity, strategic consulting experience, and serial entrepreneurs have also joined the journey, along with the backing of impact-focused funds like Decelera Ventures.
Why the buzz? Marcos Martín, CEO of Decelera Ventures, sums it up, "We invested in Ailin for its innovative approach to one of the major challenges in the health sector. Isabel's dedication and vision, backed by an experienced team, strengthen our confidence in a project paving the way for a healthier and more accessible future."
So, what's in store for Ailin with this financial boost? The investment is set to turbocharge Ailin's technological development, introducing Artificial Intelligence algorithms for more precise health diagnoses. But that's not all; a significant chunk of the funds is earmarked for talent acquisition, bolstering the Ailin team.
Isabel Caruana, CEO and founder of Ailin, is excited about the possibilities. "This investment round will propel us into developing a new market category, bringing diagnostic tests closer to homes and advocating for a health model focused on prevention."
For Ailin, the plan goes beyond the digital realm; it's about disrupting the traditional healthcare model. The goal for 2024? Forge strategic alliances, deepen collaborations with institutions like the Clínica Universidad de Navarra, and form partnerships with leading health insurers and pharmaceutical laboratories.
But let's zoom in on their products. Ailin plans to expand its kit catalog, introducing a new line for intolerances (fructose, lactose, and SIBO). These tests, affecting one in four people, empower patients to conduct them conveniently at home, with results accompanied by a health plan designed by specialists. Ailin's commitment to innovation in the health sector is further strengthened by ongoing research into biomarkers and the integration of artificial intelligence models to detect a wider range of diseases.
The Home Diagnostic Revolution
Ailin, a diagnostic support solutions platform, positions itself as a pioneer, offering a convenient, efficient, and secure way for individuals to understand and monitor their health status from the comfort of their homes, anytime they please.
The Ailin proposal rests on two fundamental pillars:
1. Self-Collection Kits: Patients can access laboratory tests from anywhere, eliminating the need to travel to a medical center.
2. Results Interpretation Software: This facilitates personalized interpretation of results by doctors in a fraction of the usual time, enabling patients to comprehend their results and take action towards achieving optimal health.
Remarkably, the startup witnessed a x7 growth in 2023, with an average monthly growth rate of 60% in the last quarter. This growth isn't just about numbers; it's rooted in addressing real user needs, evidenced by a high level of user satisfaction – their Net Promoter Score (NPS) is an impressive 72%, far surpassing the 49% of their main English competitor.
As Ailin charts its course into 2024, the ambition is to multiply revenue growth by ten and reach over 10,000 patients. With these achievements and technological strides, Ailin emerges as the go-to choice for those seeking a revolutionary and efficient approach to personalized health diagnostics accessible from the comfort of their homes.